Cancer risks among patients with alopecia areata: A population-based case-control study in Korea To the Editor: Studies have shown the reduced incidence of skin cancer in patients with autoimmune dermatologic diseases, including alopecia areata (AA) and vitiligo. 1, 2 The aim of this study was to investigate the association between AA and several types of cancer. This study was a retrospective case-control study from the National Health Insurance ServiceeNational Sample Cohort. 3 Age, sex, location, income, and diagnostic codes based on the International Classification of Diseases, 10th edition were retrieved. Patients who had International Classification of Diseases, 10th edition codes of alopecia areata (L63, L63.0, L63.1, L63.2, L63.8, or L63.9) were identified from the database. Patients were identified who had International Classification of Diseases, 10th edition codes of Graves' disease (E05, E05.0 E05.8, or E05.9), Hashimoto thyroiditis (E06.3 or E06.9), thyroid (C73), breast (C50), colorectal (C18, C19, or C20), gastric (C16), liver (C22), and lung cancer (C34). To improve the accuracy of analysis, only the subjects who had $2 principal diagnostic codes for each disease were included. Control subjects matched for age and sex were selected randomly from the database at a frequency of 1:5. The demographic characteristics of study subjects were summarized in Table I (Table II) . A decreased risk of several cancers has been observed in patients with AA, although the only published study on the association between AA and cancer was with skin cancer. 1 Interestingly, in a large study of 4.5 million men, a decreased risk of cancer was observed in patients with multiple sclerosis. The innate immune profile of patients with multiple sclerosis, characterized by increased T helper type 1 immune activation and altered cytokine levels, may inhibit carcinogenesis. 4 Based on the immunologic and genomic similarities of AA with multiple sclerosis, we thought that AA might have a similar mechanism as multiple sclerosis in inhibiting carcinogenesis. We also found a significant association between AA and thyroid cancer. There were increased risks of autoimmune thyroid disease in AA patients, so it has been postulated that the inflammatory response of thyroid diseases may induce malignant transformation of the thyroid. 5 Our study has some limitations. The diagnosis of AA and various comorbidities was identified and characterized based on the claims database without reviewing the detailed clinical charts. However, the coding error probabilities were identical between patients with AA and control subjects, and therefore no significant bias would have been introduced. Also, in Korea, the benefit extension policy is applied to all patients with cancer, so the database has a high accuracy of cancer diagnosis. This study found that patients with AA are at a decreased risk of breast, colon/rectum, stomach, lung, and liver cancer, while they have an increased risk of thyroid cancer. Decreased risk of vitiligo in organ transplant recipients: A population-based cohort study
To the Editor: Vitiligo remains a major challenge in dermatology because there is no definitive cure. 1 The autoimmune nature of vitiligo has been described, 2 and the involvement of T cells in pathogenesis of vitiligo has also been shown in previous reports. 3 While the therapeutic potential of immunosuppressants has often been raised, their role has not been well examined.
We conducted a nationwide, population-based, retrospective cohort study to investigate the risk of vitiligo in organ transplant recipients (OTRs) using Korean National Health Insurance Table I ). The most frequently used immunosuppressants in OTRs were tacrolimus (60.36%), mycophenolate mofetil (53.81%), and cyclosporine (42.44%; Table II) .
Our results may be attributed to the use of immunosuppressants in OTRs, and we speculate that the immunosuppressants could be effective in halting the spread of vitiligo as well. Although corticosteroids are the most commonly used systemic drugs for patients with spreading vitiligo, adverse effects restrict the long-term use of corticosteroids. Until now, a few case series showed conflicting results of the use of immunosuppressants other than corticosteroids for treatment of vitiligo. 4, 5 There are a few limitations in our study. First, the detailed information of individuals that may influence the results was not assessed, such as medications other than the immunosuppressive agents, lifestyle factors, original disease that indicated transplantation, personal/family history of vitiligo or autoimmune diseases, donorerecipient mismatch, and medical history of the donor. Second, the associations of individual drugs with vitiligo risk were not determined.
In conclusion, we demonstrated the association of organ transplant status with a reduced risk of vitiligo. Although our observations do not address the effectiveness of immunosuppressants, the use of immunosuppressants might be considered to manage patients with vitiligo after reviewing the risk and benefits. Additional studies are needed. 
